“Reducing costs, increasing utilisation, building deposits and improving quality of cord blood units worldwide. This is what the Cord Blood World Europe Congress aims to do, by bringing together public and private banks, clinicians, researchers, and solution providers to tackle the challenges and opportunities facing this field of regenerative medicine.”
The cord blood banking industry is one of the fastest growing industries in the world, with the number of cord blood banks increasing 21 fold in less than 10 years, but recent challenges have meant that there are still issues that need to be addressed. High costs of units due to expensive storage and extraction, a lack of available units, and a plateau in the use of cord blood for transplant and regenerative medicine mean that a meeting between key players in this area is greatly needed. Continue reading Cord Blood World Europe – Bringing together Public and Private Banks, Clinicians & Researchers→
Competing in the Stem Cell Marketplace is a Difficult Task
For executives operating a stem cell company or cord blood bank, competing in the marketplace is a difficult task. You must analyze market conditions, predict industry trends, and capitalize on market changes before the competition. Especially within the rapidly evolving stem cell marketplace, it can be difficult to make educated, informed decisions that produce revenue growth for your company, while limiting failed products that won’t have demand in the marketplace. Continue reading Need Results for Your Stem Cell Company or Cord Blood Bank? BioInformant Shares Testimonials→
Role of Patent Analysis for Competitive Intelligence
In 2006, groundbreaking experimentation led to the discovery of induced pluripotent stem cells (iPSCs), which are adult cells that are transformed into embryonic-like stem cells through the manipulation of gene expression or other related methods. In 2007, follow-up experiments proved human adult cells could be transformed into iPSC cells. Since the discovery of iPSCs, a large and thriving research product market has grown into existence, largely because the cells are completely non-controversial and can be generated directly from adult cells.
Today, the number of iPSC products sold worldwide is increasing with double-digit growth, and 22% of all stem cell researchers self-report having used iPSCs within a research project. It is clear that iPSCs represent a lucrative product market, but commercializing the cell type involves careful and due diligence, because the cells are still a relatively new discovery.
Hematopoietic Stem Cell Transplant Rates, Utilization of Cord Blood, Awareness Rates, and More
The cord blood banking market has emerged gradually over the past 40 years, as 1974 was the first year in which it was proposed that stem and progenitor cells were present in human cord blood. In the forthcoming years it was established that cord blood stem cells had similar properties as bone marrow and could be used as an alternative. Because it is a rich source of highly primitive hematopoietic stem cells, umbilical cord blood has enormous regenerative potential for stem cell based therapy, both for the treatment of hematological and non-hematological disorders. Continue reading If You’re Investing in the Cord Blood Market, You Need to Know These Metrics [Infographic]→
Best Video of 2015: “Birth and Engraftment of Blood Stem Cell”
This video published by the Harvard School of Medicine is incredible! We’ve passed it around and have awarded it the “Stem Cell Video of the Year” award.
It’s a zebrafish animation that shows the discoveries made by the Stem Cell Research Program at Boston Children’s Hospital. Using the zebrafish as a model, it takes you from the birth of a blood stem cell, along its travel through the body, to its site of engraftment.
Trend rate data is valuable for understanding current industry conditions, as well as for predicting future behavior within the cord blood industry.
In upcoming posts, we will be presenting a range of valuable trend rate data, pulled from diverse sources, including grant funding databases, patent databases, clinical trial databases, and more.
In this post, we will begin with an analysis of scientific publication rate data for cord blood industry, because it is an important way to gauge innovation and progress within the marketplace.
Scientific Publication Rate Analysis
PubMed is a service of the U.S. National Library of Medicine and the National Institutes of Health (NIH) that contains citations from MEDLINE and a diverse collection of other life science journals. The data below was generated using the PubMed database, because it is the largest, most comprehensive, and most up-to-date global meta-database available for scientific publications.
As a provider of induced pluripotent stem cell (iPSC) products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition.
To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types are showing the most promise and understanding methods through which these cells could be commercialized.
Marketing Cost Analysis for “Mesenchymal Stem Cell”
Because Google now controls over 50% of online searches, it is the single best resource available for analyzing online search behavior within the mesenchymal stem cell (MSC) market.
Identifying the cost of winning search terms related to MSCs is an important analysis for company executives to conduct, because it allows for the planning of cost-effective Google Adwords campaigns and because it reveals existing levels of market competition for the sale of MSC products and services.
Individuals or companies who choose to buy the exact search phrase “Mesenchymal Stem Cell” through Google AdWords now pay $7.65 to win search traffic for this phrase within the United States.
Internationally, when all locations are considered, the cost for buying the exact search phrase “Mesenchymal Stem Cell” through Google AdWords is $2.85. It is a valuable finding that the cost of marketing MSC products and services is more than twice as expensive within the USA as it is globally ($7.65 vs. $2.85 per click, respectively).
IMAGE. Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Geography: USA Only)
IMAGE. Google Adwords Price-Per-Click for Term “Mesenchymal Stem Cell” (Geography: Worldwide)
Findings from this section are summarized below.
TABLE. Google Adwords Pay-Per-Click Prices for the Search Phrase “Mesenchymal Stem Cell”
Mesenchymal Stem Cell
Mesenchymal Stem Cell
The Cost of Derivative Search Terms
Next, an analysis of derivative search terms that contain the phrase “Mesenchymal Stem Cell” is presented. Results containing the phrase “Stem Cell” are also included for comparative purposes. While there are often lower volumes of search for long-tail phrases, they are usually more specialized and can therefore potentially convert at higher rates.
See a full analysis of “Mesenchymal Stem Cell” derivative search terms for the United States and worldwide below, again performed using the Google Adwords tool.
IMAGE. Cost-per-Click for Derivative Search Terms (Geography: USA Only)
IMAGE. IMAGE. Cost-per-Click for Derivative Search Terms (Geography: Worldwide)
Staying informed about MSC marketing costs and current levels of market competition is valuable to company management, as well as product managers, and industry investors. There are other critical industry metrics to track as well, including MSC clinical trial rates, patent rates, scientific publication rates, and grant rates and more. However, continuously tracking these metrics is be time-consuming and expensive. To quickly access current MSC industry metrics, view the full Executive Summary and Table of Contents for the global strategic report “Mesenchymal Stem Cells – Advances & Applications” now.
Future Posts about the Stem Cell Industry
To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time. No spam ever, just great stuff.
 Adwords.google.com, (2014). Google AdWords: Keyword Planner. [online] Available at: https://adwords.google.com/ko/KeywordPlanner/Home (“Mesenchymal Stem Cell”; Geography: USA Only) [Accessed 19 May. 2015].
 Adwords.google.com, (2014). Google AdWords: Keyword Planner. [online] Available at: https://adwords.google.com/ko/KeywordPlanner/Home (“Mesenchymal Stem Cell”; Geography: Worldwide) [Accessed 19 May. 2015].
AUTHOR: Authored by Wendy Roberts, PR Director of Orca Communications Unlimited, LLC.
COMMENT BY BIOINFORMANT: Leading global players within cord blood industry frequently attain their industry dominance through industry collaborations. In the announcement below, released May 11, 2015, CariCord and ClinImmune Labs announce a major industry partnership that will study the survivability of umbilical cord blood stem cells under micro gravity (Micro-G) simulation.
CariCord, a private stem cell bank at the University of Colorado, is a FDA-licensed cord blood manufacturer that has processed nearly 9,000 cord blood units and released 700+ for transplantation across 150+ hospitals worldwide. While CariCord is not as substantial in size as other key players within the U.S. cord blood industry (most notably Cord Blood Registry, ViaCord, and Cryo-Cell, respectively) the company is positioning itself for increased visibility and growth through this strategic collaboration. Continue reading Major Industry Alliance: CariCord and ClinImmune Labs Partner with International Space Medicine Consortium→
AUTHOR: This post was written by Dr. Daniel J. Kota, a husband, father, scientist and a passionate believer in the therapeutic potential of adult stem cells. Dr. Kota has more than seven years of research experience developing treatments for myocardial infarction, diabetes and traumatic brain injury using Mesenchymal Stem/Stromal Cells. He works as a biomedical scientist focused on Adult Stem Cells at the Program in Children’s Regenerative Medicine at the University of Texas Health Science Center.
The Mesenchymal Stem Cell Journey Experienced by a Researcher
My four-year old daughter recently learned the infamous question, “Are we there yet?” As we approach almost 30 years after the discovery of mesenchymal stem cells (MSCs), it seems that effective MSC therapies should be within grasp.
“Data is boring. Put your trust in a new-age market research firm. We’re young (under 40 team), innovative, and trained in applying bioinformatics – the science of analyzing complex biological data – to the field of market research.
With 4 zettabytes of data in the world, we’ll get rid of the noise and give you just the data you need to make more revenue.”
Breaking News Just Released within the Induced Pluripotent Stem Cell (iPSC) Sector
TOKYO and MADISON, Wis., March 30, 2015
FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert Palay) (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities, announced that the two companies have entered into a agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger.
For expectant parents, there are thousands of decisions to make in a short amount of time, including clothes, cribs, names, birthing methods, medical procedures, and more. It can be overwhelming, especially given the short-time frame involved. In addition to these decisions, there is an often overlooked decision: what to do with the extremely valuable stem and progenitor cells contained within the umbilical cord of the expected newborn? There are three options, which are to publicly donate, to privately store, or to discard the umbilical cord as medical waste. Two of those decisions require research and action on behalf of the parents, while the third is what happens when sufficient awareness and education has not been provided to allow parents to make an informed, educated decision. Continue reading Save the Cord Foundation and BioInformant Join Forces in Global Effort to Increase Cord Blood Banking Awareness→
WASHINGTON and NEW YORK CITY and LONDON, April 1, 2015 /PRNewswire/ — As a leading provider of market research reports and solutions, MarketResearch.com is pleased to highlight a report by BioInformant Worldwide, LLC, indicating that 2015 will be a year of market growth and opportunity for the stem cell industry.
For executives operating a stem cell company or cord blood bank, competing in the stem cell marketplace is a difficult task. You must analyze market conditions, predict industry trends, and act on market changes before the competition. Especially within the rapidly evolving stem cell marketplace, it can be difficult to make educated, informed decisions that produce revenue growth, while limiting failed products.
BioInformant specializes exclusively in stem cell market research and is the only research firm that has been tracking the market since it emerged. Because there are hematopoietic stem cells in cord blood and mesenchymal stem cells in cord tissue, BioInformant has also been tracking the cord blood industry since 2006. One of BioInformant’s most popular global strategic reports is the “Complete 2015-16 Global Cord Blood Banking Industry Report.”
Published to assist company leaders and cord blood industry investors, this global cord blood report is designed to increase efficiency and effectiveness in:
Communicating effectively with existing and potential clients
Launching high-demand products and services
Taking market share from your competition
Commercializing cord blood products, technologies, and therapies
Making intelligent investment decisions
The global cord blood market has matured substantially over the past few years, creating both novel opportunities and serious threats. Serious threats to the industry include new accreditation requirements that have increased the cost structure of cord blood banks, a recent decline in cord blood transplants, low rates of turnover for stored cord blood units, difficulty with educating obstetricians about cellular therapies, and more. Marketing pressures are also impacting the industry, with the term “cord blood” becoming one of the 20 most expensive search terms on Google, reaching more than $20 per click for global search traffic and close to $40 per click for U.S. search traffic.
Additionally, awareness rates are limiting market potential. A study published in the Journal of Reproductive Medicine identified that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as “minimally informed.” A recent “Parent Survey” conducted by BioInformant Worldwide, LLC that incorporated 600+ responses from recent and expectant parents identified that awareness percentages have shifted little since the prior study was published.
However, there are also substantial opportunities for company executives who are positioned to take advantage of them, including the potential to expand the cord blood market through increased awareness, new clinical trial data supporting applications for hematopoietic stem cells (HSCs), improving public perception toward stem cell therapies, substantial deal-making within the industry, an industry trend toward diversified bio-banking, and much more.
Within the rapidly evolving stem cell marketplace, individuals who commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage. Some stem cell companies and cord blood banks will make expensive new hires or a maintain business developments in an effort to compete, but you don’t need to. For a much smaller investment, you can immediately make informed, educated decisions about your marketplace.
BioInformant’s stem cell market research is also available on www.profound.com, where subscribers are able to purchase only the individual sections, chapters, tables or charts of a report they need without having to pay for the pieces they don’t.
About MarketResearch.com MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world’s most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com’s Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance.
About BioInformant Worldwide BioInformant specializes in global strategic reports for the stem cell industry and is the only research firm that has served the stem cell sector since it emerged. BioInformant research has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, and more. In addition, BioInformant’s management team comes from a “bioinformatics” background, the science of collecting and analyzing complex genetic codes. We are trained in applying these data analysis techniques to the field of market research. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your trusted source of stem cell industry data.
WideCells is a new and innovative stem cell technology and regenerative medicine company. It was founded by the CEO João Andrade and the CFO Lopes Gil. Dr Peter Hollands later joined as CSO bringing experience from other UK and international stem cell banks, clinical transplantation, teaching and research.
The first operations for WideCells were in Portugal, following on to the acquisition of the Spanish company Nacersalud to begin operations in Spain.
The cord blood banking market is rapidly evolving. Major research advances are announced every month. Innovation is the only constant.
Under these circumstances, it is difficult to track the ever-changing landscape of the cord blood banking market. Therefore, these scholarly research round-ups highlight “must know” research advances occurring in the sector, both those published by extremely well-regarded researchers (such as Joanne Kurtzberg’s article below), as well as those published by up-and-coming scientists. Continue reading Cord Blood Scholarly Research Round-Up [March 2015]→
An interesting aspect of the stem cell therapy market as it stands today is that autologous stem cell therapies are regulated by the U.S. Food and Drug Administration (FDA) as a “drug.”
Stem cells, such as hematopoietic stem cells that have been used for decades in bone marrow transplants, can be extracted from an individual, and on the same day, can be re-injected into a specific site that needs repair. When the cells are sourced from and implanted into the same person this is called an autologous transplant.
Regenexx Stem Cell Procedure
One of the most well-known of these approaches is the Regenexx procedure. You’ll have a very difficult time finding negative press about the procedure from patients, despite that many patients have paid several thousand dollars “out-of-pocket” to access the care, as it is typically not covered by health insurance carriers in the United States.
The reason is that the results are often outstanding. I am an example of a patient whose life was transformed by the procedure. I’m currently taking action to get access to my own “before” and “after” MRI of my knee damage that was addressed through stem cell regeneration. I have my before MRI, but am in the process of acquiring my post-treatment MRI, as I just reach my one-year anniversary of the transplant.
In the meantime, here is a before and after MRI of another patient’s knee showing positive clinical results from the Regenexx procedure:
How Regulation of Autologous Stem Cell Procedures Affects the Global Stem Cell Market
As a stem cell research firm, the question that interests me most (and the question that will interest most of our readers who are executives at stem cell companies or stem cell industry investors) is how will the current regulation of autologous stem cells as a “drug” affect the broader stem cell marketplace?
If regulations in the United States that treat autologous stem cell as a drug do not change, then other countries, most notably Japan and Canada, but also United Kingdom, Australia, and others, will soon outpace the U.S. in this area of medicine.
Furthermore, for-profit companies in the U.S. will not have financial incentives to invest in the development of autologous stem cell treatments.
For the stem cell market at large, continued regulation of autologous stem cells as drugs within the United States will cause more money to flow overseas, followed by more jobs, more talent, and more research advances. Without regulatory change, the epicenter of the stem cell market will not be the United States. Japan is moving forward rapidly with stem cell based cellular therapy development, and in many respects, has already out-paced the U.S.
Are Stem Cells Different from Current Surgical Tissue Grafts?
When considering autologous stem cell regulation, an important question to ask is whether the use of autologous stem cells for therapeutic purposes should be considered as substantially different from current procedures. For instance, in many surgical procedures, including traditional approaches to ACL repair, a graft is taken from another site of a patient’s body and placed into a different part of the body. One of the best-known examples of this is an approach for anterior cruciate ligament ( ACL) reconstruction that removes part of a patient’s hamstring tendon for use as a new ACL “substitute.” This procedure is known as Hamstring Tendon Graft Reconstruction (HTGR).
This comparison raises the question, are stem cells that have originated in you a “drug,” or do you and your doctor have a right to use them for therapeutic purposes, as surgeons have done for decades?
“Special” and “Designer” Stem Cells
Naturally, there are different types of stem cells, and some come with greater complications and risks than others. For instance, there might be greater value in the regulation of stem cells that are sourced from another individual, a procedure known as an “allogenic” stem cell transplant. (“Allogenic” means coming from another.)
There are also embryonic stem cells (ESCs), which must be derived from embryos at fertility clinics. Note that the same embryos used to derive ESCs would be discarded or eventually die if they were not used to derive ESCs, because embryos cannot be indefinitely preserved. It is no more possible for an embryo to life indefinitely than it is for a human being to live forever.
There are also induced pluripotent stem cells (iPSC), which are adult cells that are reverse engineered to be pluripotent in nature, allowing them to have the potential to become a diverse range of adult cell types. Functionally, they are quite similar to embryonic stem cells in their therapeutic potential.
However, these “special” and “designer” stem cell types must not be compared to the basic hematopoietic stem cells that travel throughout an adult body, highly concentrated in specific regions such as the bone marrow. These autologous stem cells are intrinsic to every living being.
For that reason, I leave you today’s powerful quote, not as an answer, but as fuel for intellectual curiosity:
Note: Click to enlarge image.
Enjoy, comment, and get in on this discussion of how autologous (“self”) stem cells should or should not be regulated!
Future Posts about the Stem Cell Industry
To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time. No spam ever, just great stuff.
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and Thermo Fisher Scientific, BioInformant is your global leader in stem cell industry data. To learn more about emerging opportunities and threats within the stem cell market, view our global strategic reports for the stem cell industry.